BioCentury
ARTICLE | Finance

3Q Financial Markets Preview: Miles of milestones

2H12 has at least 117 major clinical, regulatory events for biotech

July 2, 2012 7:00 AM UTC

A deep line-up of milestones could help retain gains the sector has been holding onto since 1Q12. In particular, investors would love to see further breakthroughs in difficult areas such as Alzheimer's disease and obesity.

Top of mind for almost every specialist investor are Phase III data in Alzheimer's disease that are due this quarter - even though none of these buysiders expect the data to be positive...